中国医药
中國醫藥
중국의약
CHINA MEDICINE
2013年
2期
210-212
,共3页
子宫内膜肿瘤%脆性组氨酸三联体%半胱氨酸蛋白酶3
子宮內膜腫瘤%脆性組氨痠三聯體%半胱氨痠蛋白酶3
자궁내막종류%취성조안산삼련체%반광안산단백매3
Endometrial neoplasms%Fragile histidine triad%Caspase-3
目的 探讨脆性组氨酸三联体(FHIT)和半胱氨酸蛋白酶3(caspase-3)蛋白在子宫内膜腺癌发生、发展过程中的可能作用.方法 选择子宫内膜腺癌患者(腺癌组,60例)、子宫内膜不典型增生患者(不典型增生组,30例)和子宫肌瘤切除术患者(对照组,正常子宫内膜30例)作为研究对象.采用免疫组织化学(免疫组化)SP法检测3组中FHIT、caspase-3蛋白的表达,结合临床病理特征进行分析.结果 FHIT在腺癌组、不典型增生组和对照组的阳性表达率分别为53.3％ (32/60)、63.3％ (19/30)和100％(30/30),caspase-3的阳性表达率分别为51.7％ (31/60)、70.0％ (21/30)和86.7％ (26/30),腺癌组FHIT、caspase-3的阳性表达率明显低于对照组,差异均有统计学意义(均P＜0.01).FHIT与caspase-3的阳性表达均与子宫内膜腺癌的组织分级(G1、G2 ～3)有关(x2=9.312、14.299,均P＜0.01),FHIT还与子宫内膜腺癌的手术-病理分期(Ⅰ～Ⅱ、Ⅲ～Ⅳ)、肌层浸润(≤1/2、＞1/2)和淋巴转移(阴性、阳性)有关(均P＜0.05).结论 FHIT和caspase-3可能与子宫内膜腺癌的发生均有关.FHIT和CASPASE-3联合检测有利于子宫内膜腺癌的早期诊断及判断预后.
目的 探討脆性組氨痠三聯體(FHIT)和半胱氨痠蛋白酶3(caspase-3)蛋白在子宮內膜腺癌髮生、髮展過程中的可能作用.方法 選擇子宮內膜腺癌患者(腺癌組,60例)、子宮內膜不典型增生患者(不典型增生組,30例)和子宮肌瘤切除術患者(對照組,正常子宮內膜30例)作為研究對象.採用免疫組織化學(免疫組化)SP法檢測3組中FHIT、caspase-3蛋白的錶達,結閤臨床病理特徵進行分析.結果 FHIT在腺癌組、不典型增生組和對照組的暘性錶達率分彆為53.3％ (32/60)、63.3％ (19/30)和100％(30/30),caspase-3的暘性錶達率分彆為51.7％ (31/60)、70.0％ (21/30)和86.7％ (26/30),腺癌組FHIT、caspase-3的暘性錶達率明顯低于對照組,差異均有統計學意義(均P＜0.01).FHIT與caspase-3的暘性錶達均與子宮內膜腺癌的組織分級(G1、G2 ～3)有關(x2=9.312、14.299,均P＜0.01),FHIT還與子宮內膜腺癌的手術-病理分期(Ⅰ～Ⅱ、Ⅲ～Ⅳ)、肌層浸潤(≤1/2、＞1/2)和淋巴轉移(陰性、暘性)有關(均P＜0.05).結論 FHIT和caspase-3可能與子宮內膜腺癌的髮生均有關.FHIT和CASPASE-3聯閤檢測有利于子宮內膜腺癌的早期診斷及判斷預後.
목적 탐토취성조안산삼련체(FHIT)화반광안산단백매3(caspase-3)단백재자궁내막선암발생、발전과정중적가능작용.방법 선택자궁내막선암환자(선암조,60례)、자궁내막불전형증생환자(불전형증생조,30례)화자궁기류절제술환자(대조조,정상자궁내막30례)작위연구대상.채용면역조직화학(면역조화)SP법검측3조중FHIT、caspase-3단백적표체,결합림상병리특정진행분석.결과 FHIT재선암조、불전형증생조화대조조적양성표체솔분별위53.3％ (32/60)、63.3％ (19/30)화100％(30/30),caspase-3적양성표체솔분별위51.7％ (31/60)、70.0％ (21/30)화86.7％ (26/30),선암조FHIT、caspase-3적양성표체솔명현저우대조조,차이균유통계학의의(균P＜0.01).FHIT여caspase-3적양성표체균여자궁내막선암적조직분급(G1、G2 ～3)유관(x2=9.312、14.299,균P＜0.01),FHIT환여자궁내막선암적수술-병리분기(Ⅰ～Ⅱ、Ⅲ～Ⅳ)、기층침윤(≤1/2、＞1/2)화림파전이(음성、양성)유관(균P＜0.05).결론 FHIT화caspase-3가능여자궁내막선암적발생균유관.FHIT화CASPASE-3연합검측유리우자궁내막선암적조기진단급판단예후.
Objective To detect the expression of the fragile histidine triad(FHIT) and caspase-3 protein in endometrial adenocarcinoma (EC),endometrial atypical hyperplasia (EIN) and the normal endometrium.To explore the relation between FHIT and caspase-3 in the genesis and progression of endometrial carcinoma.Methods The expression of FHIT and caspase-3 protein in 60 cases of EC,30 cases of EIN and 30 cases of normal endometrial tissue were detected by streptavidin-peroxidase (SP) immunohistochemical staining.The clinicopathological characteristics of patients and the relevance of FHIT and caspase-3 were analyzed.Results The positive rates of FHIT in EC,EIN and normal endometrium were 53.3％ (32/60),63.3％ (19/30) and 100.0％(30/30),respectively.The positive rates of caspase-3 in EC and EIN and normal endometrium were 51.7％ (31/60),70.0％ (21/30),86.7％ (26/30),respectively.The positive rates of FHIT and caspase-3 in EC were significantly lower than those in normal endometrium,the difference was statistically significant (P ＜ 0.01).Thepositive expressions of FHIT and caspase-3 were all related to the organizational grade of EC (G1:x2 =9.312,G2-3:x2 =14.299,all P ＜ 0.01).The positive expressions of FHIT was associated with the surgical-pathologic staging of EC(Ⅰ-Ⅱ,Ⅲ-Ⅳ),myometrial invasion (≤1/2,＞ 1/2) and lymph node metastasis (negative,positive) (all P ＜ 0.05).Conclusions FHIT and caspase-3 may be associated with the occurrence of endometrial adenocarcinoma.The combined detection of FHIT and caspase-3 protein may become important indexes of early diagnosis and forecasting of EC.
